186 related articles for article (PubMed ID: 17192125)
1. Effect of olmesartan medoxomil on atherosclerosis: clinical implications of the emerging evidence.
Takai S; Miyazaki M
Am J Cardiovasc Drugs; 2006; 6(6):363-6. PubMed ID: 17192125
[TBL] [Abstract][Full Text] [Related]
2. Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil.
Mason RP
Vasc Health Risk Manag; 2011; 7():405-16. PubMed ID: 21796255
[TBL] [Abstract][Full Text] [Related]
3. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation.
Fliser D; Buchholz K; Haller H;
Circulation; 2004 Aug; 110(9):1103-7. PubMed ID: 15313950
[TBL] [Abstract][Full Text] [Related]
4. Antagonizing the angiotensin II subtype 1 receptor: a focus on olmesartan medoxomil.
Nussberger J; Koike H
Clin Ther; 2004; 26 Suppl A():A12-20. PubMed ID: 15291375
[TBL] [Abstract][Full Text] [Related]
5. Olmesartan medoxomil: current status of its use in monotherapy.
Brunner HR
Vasc Health Risk Manag; 2006; 2(4):327-40. PubMed ID: 17323586
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacological profiles and clinical effects of olmesartan medoxomil, a novel angiotensin II receptor blocker].
Sada T; Mizuno M
Nihon Yakurigaku Zasshi; 2004 Oct; 124(4):257-69. PubMed ID: 15467259
[TBL] [Abstract][Full Text] [Related]
7. Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor.
Hasler C; Nussberger J; Maillard M; Forclaz A; Brunner HR; Burnier M
Clin Pharmacol Ther; 2005 Nov; 78(5):501-7. PubMed ID: 16321616
[TBL] [Abstract][Full Text] [Related]
8. Clinical and experimental aspects of olmesartan medoxomil, a new angiotensin II receptor antagonist.
Yoshida K; Kohzuki M
Cardiovasc Drug Rev; 2004; 22(4):285-308. PubMed ID: 15592575
[TBL] [Abstract][Full Text] [Related]
9. Olmesartan medoxomil: the seventh angiotensin receptor antagonist.
Gardner SF; Franks AM
Ann Pharmacother; 2003 Jan; 37(1):99-105. PubMed ID: 12503943
[TBL] [Abstract][Full Text] [Related]
10. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.
Kusumoto K; Igata H; Ojima M; Tsuboi A; Imanishi M; Yamaguchi F; Sakamoto H; Kuroita T; Kawaguchi N; Nishigaki N; Nagaya H
Eur J Pharmacol; 2011 Nov; 669(1-3):84-93. PubMed ID: 21816148
[TBL] [Abstract][Full Text] [Related]
11. Combined treatment with olmesartan medoxomil and amlodipine besylate attenuates atherosclerotic lesion progression in a model of advanced atherosclerosis.
Sievers P; Uhlmann L; Korkmaz-Icöz S; Fastner C; Bea F; Blessing E; Katus HA; Preusch MR
Drug Des Devel Ther; 2015; 9():3935-42. PubMed ID: 26251572
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.
Barrios V; Boccanelli A; Ewald S; Girerd X; Heagerty A; Krzesinski JM; Lins R; Rodicio J; Stefenelli T; Woittiez A; Böhm M
Clin Drug Investig; 2007; 27(8):545-58. PubMed ID: 17638395
[TBL] [Abstract][Full Text] [Related]
13. [Clinical profiles of new angiotensin II receptor blockers: telmisartan, olmesartan medoxomil, and irbesartan].
Ishii M
Nihon Rinsho; 2004 Jan; 62(1):193-202. PubMed ID: 14737853
[TBL] [Abstract][Full Text] [Related]
14. Olmesartan medoxomil: an angiotensin II-receptor blocker.
Brousil JA; Burke JM
Clin Ther; 2003 Apr; 25(4):1041-55. PubMed ID: 12809956
[TBL] [Abstract][Full Text] [Related]
15. Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil.
Ferrario C
Vasc Health Risk Manag; 2009; 5(1):301-14. PubMed ID: 19436655
[TBL] [Abstract][Full Text] [Related]
16. A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker.
Mire DE; Silfani TN; Pugsley MK
J Cardiovasc Pharmacol; 2005 Nov; 46(5):585-93. PubMed ID: 16220064
[TBL] [Abstract][Full Text] [Related]
17. Olmesartan medoxomil: in children and adolescents with hypertension.
Muir VJ; Keating GM
Drugs; 2010 Dec; 70(18):2439-47. PubMed ID: 21142262
[TBL] [Abstract][Full Text] [Related]
18. An angiotensin II type-I receptor blocker, olmesartan medoxomil, attenuates lipid peroxidation in renal injury induced by subtotal nephrectomy.
Takahashi T; Konta T; Takasaki S; Ichikawa K; Takeishi Y; Kubota I
Clin Exp Nephrol; 2007 Sep; 11(3):202-208. PubMed ID: 17891346
[TBL] [Abstract][Full Text] [Related]
19. Olmesartan medoxomil.
Warner GT; Jarvis B
Drugs; 2002; 62(9):1345-53; discussion 1354-6. PubMed ID: 12076183
[TBL] [Abstract][Full Text] [Related]
20. The role of olmesartan medoxomil in the management of hypertension.
Unger T; McInnes GT; Neutel JM; Böhm M
Drugs; 2004; 64(24):2731-9. PubMed ID: 15563246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
